LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Stock List・Guardant Health Inc

Guardant Health Inc

Closed

SectorHealthcare

125 -6

Buy Sell

Overview

Share price change

24h

Current

Min

124.92

Max

127.69

Key metrics
By Trading Economics
Income	16M -112M
Sales	20M 302M
EPS	-0.45
Profit margin	-37.152
Employees	2,490
EBITDA	18M -101M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+2.92% upside

Dividends
By Dow Jones
Next Earnings	29 Jul 2026

Market Stats
By TradingEconomics
Market Cap	5B 17B
Previous open	131
Previous close	125

News Sentiment

By Acuity

50%

155 / 344 Healthcare

Guardant Health Inc Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2026, 19:20 UTC

Major Market Movers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 Jun 2026, 21:27 UTC

Earnings

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 Jun 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 Jun 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 Jun 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 Jun 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 Jun 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 Jun 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 Jun 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 Jun 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 Jun 2026, 18:33 UTC

Acquisitions, Mergers, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 Jun 2026, 17:50 UTC

Earnings

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 Jun 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 Jun 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 Jun 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2026, 15:44 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 Jun 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 Jun 2026, 15:25 UTC

Earnings

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 Jun 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Jun 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 Jun 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 Jun 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 Jun 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer Comparison

Price change

Guardant Health Inc Forecast

Price Target

By TipRanks

2.92% upside

12 Months Forecast

Average 136.94 USD 2.92%

High 160 USD

Low 120 USD

Based on 18 Wall Street analysts offering 12 month price targets forGuardant Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to Guardant Health Inc - Dist in the past 3 months.

Sentiment

By Acuity

155 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.